Clinical Trial Update: ST266 Eye Drops for the Treatment of Persistent Corneal Epithelial Defects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ST266 Eye Drops in persistent corneal epithelial defects completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Corneal Epithelial Defect

Drugs mentioned

• ST266 Eye Drops

Snippet

Sponsor: Noveome Biotherapeutics, formerly Stemnion | Conditions: Persistent Corneal Epithelial Defect | Phase 2 | Status: COMPLETED